association
Full identifier: http://purl.org/np/RAq-HIAps08ZK83Y3U-6n7u-qfnOhbnujVFQQ1fvQuITo#association
Assigned to 1 class:
Minted in Nanopublication
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
http://www.w3.org/2000/01/rdf-schema#label
has label
(this is a literal)
"carefully consider the potential benefits and risks of celebrex and other treatment options before deciding to use celebrex use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings and precautions 5 celebrex is a nonsteroidal anti inflammatory drug indicated for osteoarthritis oa 1 1 rheumatoid arthritis ra 1 2 juvenile rheumatoid arthritis jra in patients 2 years and older 1 3 ankylosing spondylitis as 1 4 acute pain ap 1 5 primary dysmenorrhea pd 1 6 familial adenomatous polyposis fap adjunct to usual care 1 7 celebrex is indicated for relief of the signs and symptoms of oa see clinical studies 14 1 celebrex is indicated for relief of the signs and symptoms of ra see clinical studies 14 2 celebrex is indicated for relief of the signs and symptoms of jra in patients 2 years and older see clinical studies 14 3 celebrex is indicated for the relief of signs and symptoms of as see clinical studies 14 4 celebrex is indicated for the management of ap in adults see clinical studies 14 5 celebrex is indicated for the treatment of pd see clinical studies 14 5 celebrex is indicated to reduce the number of adenomatous colorectal polyps in fap as an adjunct to usual care e g endoscopic surveillance surgery it is not known whether there is a clinical benefit from a reduction in the number of colorectal polyps in fap patients it is also not known whether the effects of celebrex treatment will persist after celebrex is discontinued the efficacy and safety of celebrex treatment in patients with fap beyond six months have not been studied see warnings and precautions 5 15 clinical studies 14 6"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
has drug
https://identifiers.org/drugbank:DB00482
drugbank:DB00482
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
has disease
http://purl.obolibrary.org/obo/DOID_7147
DOID_7147
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
https://w3id.org/biolink/vocab/relation
has relation
https://schema.org/TreatmentIndication
An indication for treating an underlying condition.
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
https://w3id.org/biolink/vocab/association_type
has BioLink type
https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation
ChemicalToDiseaseOrPhenotypicFeatureAssociation
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
has type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
association Statement
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
has predicate
https://w3id.org/biolink/vocab/treats
treats
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#association
This association
https://w3id.org/biolink/vocab/provided_by
is provided by
https://w3id.org/um/NeuroDKG
NeuroDKG
.
This is the identifier for the assertion of this nanopublication.
http://purl.org/np/RAq-HIAps0...#assertion
The assertion above
http://www.w3.org/ns/prov#wasAttributedTo
is attributed to
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
This nanopublication
http://purl.org/dc/terms/creator
is created by
https://orcid.org/0000-0002-1468-3557
me (Leoni Bücken)
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
This nanopublication
date and time when the nanopublication was created
http://purl.org/dc/terms/created
was created on
(this is a literal)
"2021-07-03T11:39:18.861+02:00"
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
This nanopublication
links to the assertion template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
was created from the assertion template
http://purl.org/np/RAManV5GZI...
RAManV5GZI
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
This nanopublication
links to the provenance template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
was created from the provenance template
http://purl.org/np/RANwQa4ICW...
RANwQa4ICW
.
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
This nanopublication
links to the publication info template that was used to create this nanopublication
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
was created from the publication info template
http://purl.org/np/RAA2MfqdBC...
RAA2MfqdBC
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget
has as target
This is the identifier for this whole nanopublication.
http://purl.org/np/RAq-HIAps0...
this nanopublication
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm
has the algorithm
(this is a literal)
"RSA"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#sig
sig
http://purl.org/nanopub/x/hasPublicKey
has the public key
(this is a literal)
"MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
.
This is a local identifier minted within the nanopublication.
http://purl.org/np/RAq-HIAps0...#sig
sig
http://purl.org/nanopub/x/hasSignature
has the signature
(this is a literal)
"LJ/MnDUKHjnB2NCHX+nZ0hdxNX1ARcCLtV2zW5yGQ27xVCKy4jVIyWpDVuoozFBLbpq7F2BisHhUGZ4TYm0ejQNkjKGdF3NNFT4b95lRde8KVqANnAyPLPRKJT6/jMcXTmGWkUc+/Ei+rVAXj0UnbpHQ1QcPZ6E2wdHcMaMRlGs="
.
References
Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
---|---|---|---|---|---|---|
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
carefully consider the potential benefits and risks of celebrex and other treatment options before deciding to use celebrex use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings and precautions 5 celebrex is a nonsteroidal anti inflammatory drug indicated for osteoarthritis oa 1 1 rheumatoid arthritis ra 1 2 juvenile rheumatoid arthritis jra in patients 2 years and older 1 3 ankylosing spondylitis as 1 4 acute pain ap 1 5 primary dysmenorrhea pd 1 6 familial adenomatous polyposis fap adjunct to usual care 1 7 celebrex is indicated for relief of the signs and symptoms of oa see clinical studies 14 1 celebrex is indicated for relief of the signs and symptoms of ra see clinical studies 14 2 celebrex is indicated for relief of the signs and symptoms of jra in patients 2 years and older see clinical studies 14 3 celebrex is indicated for the relief of signs and symptoms of as see clinical studies 14 4 celebrex is indicated for the management of ap in adults see clinical studies 14 5 celebrex is indicated for the treatment of pd see clinical studies 14 5 celebrex is indicated to reduce the number of adenomatous colorectal polyps in fap as an adjunct to usual care e g endoscopic surveillance surgery it is not known whether there is a clinical benefit from a reduction in the number of colorectal polyps in fap patients it is also not known whether the effects of celebrex treatment will persist after celebrex is discontinued the efficacy and safety of celebrex treatment in patients with fap beyond six months have not been studied see warnings and precautions 5 15 clinical studies 14 6
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|
|||
links a nanopublication to its assertion
http://www.nanopub.org/nschema#hasAssertion
assertion
|
association
|
Leoni Bücken
|
2021-07-03T09:39:18.861Z
|